The ALPMY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ALPMY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ALPMY Detailed Price Forecast - CNN Money||View ALPMY Detailed Summary - Google Finance|
|View ALPMY Detailed Summary - Yahoo! Finance||View ALPMY Stock Research & Analysis - Zacks.com|
|View ALPMY Trends & Analysis - Trade-Ideas||View ALPMY Major Holders - Barrons|
|View ALPMY Call Transcripts - NASDAQ||View ALPMY Breaking News & Analysis - Seeking Alpha|
|View ALPMY Annual Report - CompanySpotlight.com||View ALPMY OTC Short Report - OTCShortReport.com|
|View ALPMY Fundamentals - TradeKing||View ALPMY SEC Filings - Bar Chart|
|View Historical Prices for ALPMY - The WSJ||View Performance/Total Return for ALPMY - Morningstar|
|View the Analyst Estimates for ALPMY - MarketWatch||View the Earnings History for ALPMY - CNBC|
|View the ALPMY Earnings - StockMarketWatch||View ALPMY Buy or Sell Recommendations - MacroAxis|
|View the ALPMY Bullish Patterns - American Bulls||View ALPMY Short Pain Metrics - ShortPainBot.com|
|View ALPMY Stock Mentions - StockTwits||View ALPMY Stock Mentions - PennyStockTweets|
|View ALPMY Stock Mentions - Twitter||View ALPMY Investment Forum News - Investor Hub|
|View ALPMY Stock Mentions - Yahoo! Message Board||View ALPMY Stock Mentions - Seeking Alpha|
|View Insider Transactions for ALPMY - SECform4.com||View Insider Transactions for ALPMY - Insider Cow|
|View ALPMY Major Holdings Summary - CNBC||View Insider Disclosure for ALPMY - OTC Markets|
|View Insider Transactions for ALPMY - Yahoo! Finance||View Institutional Holdings for ALPMY - NASDAQ|
|View ALPMY Stock Insight & Charts - FinViz.com||View ALPMY Investment Charts - StockCharts.com|
|View ALPMY Stock Overview & Charts - BarChart||View ALPMY User Generated Charts - Trading View|
Pfizer, Astellas revise two cancer drug trial protocols to speed up results
Posted on Wednesday August 22, 2018
The companies now expect the ARCHES trial to end late this year, ahead of the previously anticipated completion date of April 2020, and the EMBARK trial to complete by mid-2020, earlier than the prior goal of March 2021. Both trials are testing Xtandi in men with hormone-sensitive prostate cancer. Xtandi is already approved in the United States to treat castration-resistant prostate cancer and brought Pfizer revenue of $171 million in the latest reported quarter.
[$$] Astellas Pharma Buys U.K.'s Quethera
Posted on Friday August 10, 2018
Astellas Pharma Inc. said Friday it acquired Quethera Ltd., a U.K. company focused on developing treatments for ocular disorders such as glaucoma.
Astellas Announces Acquisition of Quethera
Posted on Friday August 10, 2018
TOKYO and CAMBRIDGE, England, Aug. 10, 2018 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa,Ph.D., "Astellas") and Quethera Limited (CEO: Peter Widdowson, Ph.D., "Quethera") today announced that Astellas has acquired Quethera, a gene therapy company headquartered in the United Kingdom, that is focused on developing novel treatments for ocular disorders, such as glaucoma.
Astellas Is Considering Selling Europe Assets to Raise Cash
Posted on Wednesday July 18, 2018
Astellas Pharma Inc. is considering a sale of some central and eastern European assets as the Japanese drugmaker seeks to trim its portfolio and raise cash, according to people familiar with the matter. Astellas is working with Jefferies Financial Group Inc. on the potential disposal, which includes Russian assets and has drawn interest from private equity firms and other pharmaceutical companies, the people said, asking not to be identified because the deliberations are private. The portfolio under review includes drugs to prevent infections and pain treatments, the people said.